NeuBase Therapeutics Inc (NBSE)
0.39
-0.02
(-4.62%)
USD |
NASDAQ |
May 09, 15:03
NeuBase Therapeutics Enterprise Value: -11.05M for May 8, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 08, 2024 | -11.05M |
| May 07, 2024 | -11.08M |
| May 06, 2024 | -11.04M |
| May 03, 2024 | -11.06M |
| May 02, 2024 | -11.03M |
| May 01, 2024 | -11.02M |
| April 30, 2024 | -11.02M |
| April 29, 2024 | -11.01M |
| April 26, 2024 | -10.93M |
| April 25, 2024 | -10.92M |
| April 24, 2024 | -11.00M |
| April 23, 2024 | -11.00M |
| April 22, 2024 | -11.00M |
| April 19, 2024 | -10.97M |
| April 18, 2024 | -10.95M |
| April 17, 2024 | -11.00M |
| April 16, 2024 | -11.07M |
| April 15, 2024 | -11.01M |
| April 12, 2024 | -10.93M |
| April 11, 2024 | -11.04M |
| April 10, 2024 | -11.07M |
| April 09, 2024 | -11.10M |
| April 08, 2024 | -11.05M |
| April 05, 2024 | -11.08M |
| April 04, 2024 | -10.97M |
| Date | Value |
|---|---|
| April 03, 2024 | -10.90M |
| April 02, 2024 | -10.98M |
| April 01, 2024 | -10.93M |
| March 28, 2024 | -10.89M |
| March 27, 2024 | -10.95M |
| March 26, 2024 | -10.78M |
| March 25, 2024 | -8.841M |
| March 22, 2024 | -8.729M |
| March 21, 2024 | -8.729M |
| March 20, 2024 | -8.580M |
| March 19, 2024 | -8.729M |
| March 18, 2024 | -8.804M |
| March 15, 2024 | -8.957M |
| March 14, 2024 | -9.177M |
| March 13, 2024 | -9.135M |
| March 12, 2024 | -9.028M |
| March 11, 2024 | -9.073M |
| March 08, 2024 | -9.100M |
| March 07, 2024 | -9.204M |
| March 06, 2024 | -9.214M |
| March 05, 2024 | -9.158M |
| March 04, 2024 | -9.315M |
| March 01, 2024 | -9.233M |
| February 29, 2024 | -9.363M |
| February 28, 2024 | -9.307M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-17.12M
Minimum
Dec 19 2022
260.32M
Maximum
Jun 18 2020
57.12M
Average
33.00M
Median
Dec 29 2021
Enterprise Value Benchmarks
| Ampio Pharmaceuticals Inc | -3.776M |
| Stoke Therapeutics Inc | 426.01M |
| ABVC BioPharma Inc | 12.79M |
| MAIA Biotechnology Inc | 55.42M |
| Aprea Therapeutics Inc | 6.277M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.821M |
| Total Expenses (Quarterly) | 1.591M |
| EPS Diluted (Quarterly) | -0.66 |
| Earnings Yield | -1.97K% |